報價延遲最少15分鐘:2024/12/23 22:10 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.98 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.74/-0.57
|
|
企業價值
192.50M
|
| 資產負債 |
|
每股賬面淨值
-0.48
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
1.36M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/23 22:10 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies. |